Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 68 resultados

MADCAM: Microbiota controlled trafficking of immunosuppressive intestinal T cells into cancer INSTITUT GUSTAVE ROUSSY tramitó un HORIZON EUROPE: ERC-2023-ADG Resistance of cancers to immune checkpoint blockade (ICB) can result from a deviated taxonomic composition of the intestinal microbiota. A s...
2024-09-13 - 2029-09-30 | Financiado

VIDA: VHIO International postDoctoral programme for translAtional research INSTITUT GUSTAVE ROUSSY participó en un HORIZON EUROPE: HORIZON-MSCA-2023-COFUND-01 The proposed VHIO International postDoctoral programme for translAtional research (VIDA) aims at enabling outstanding junior scientists of a...
2024-09-12 - 2029-12-31 | Financiado

T-RAFIC: Training network for tracking and controlling therapeutic immune cells in cancer Cancer immunotherapies have been established in a growing number of clinical indications and the pace of development is massively accelerat...
2024-07-16 - 2029-03-31 | Financiado

TREATLIVMETS: Treating Liver Metastasis INSTITUT GUSTAVE ROUSSY participó en un HORIZON EUROPE: ERC-2023-SyG Liver metastases commonly develop in up to 50% of patients with various cancer types. The most common cancer that metastasizes to the liver...
2024-06-11 - 2030-06-30 | Financiado

e-QuoL: e health tools to promote Equality in Quality of Life for childhood to young adulthood cancer patien... INSTITUT GUSTAVE ROUSSY participó en un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 Cancer affects 35,000 children, adolescents and young adults (CAYAC) in Europe each year. Current 5-year survival rates are 80%, but the int...
2023-12-13 - 2027-12-31 | Financiado

RealCare: Real-time biomarker detection systems for rapid medical decision-making in cancer and cardiac diseas... INSTITUT GUSTAVE ROUSSY participó en un HORIZON EUROPE: HORIZON-HLTH-2023-TOOL-05 RealCare is a cutting-edge research initiative focused on developing and validating next-generation point-of-care (PoC) systems that detect...
2023-11-17 - 2028-11-30 | Financiado

CARE1: First line randomized study platform to optimize treatment in patients with metastatic renal cell ca... INSTITUT GUSTAVE ROUSSY tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 In 2020, there were an estimated 431 288 new cases of kidney cancer (Renal Cell Carcinoma, RCC) globally with 138 611 cases in Europe, leadi...
2023-05-01 - 2028-04-30 | Financiado

PragmaTIL: Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in sele... INSTITUT GUSTAVE ROUSSY participó en un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 The PragmaTIL trial aims to optimize treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and s...
2023-04-28 - 2028-03-31 | Financiado

TargetSWItch: Targeting SWI/SNF-related chromatin remodelling defects in solid tumours INSTITUT GUSTAVE ROUSSY tramitó un HORIZON EUROPE: ERC-2022-STG Recent large-scale genomic profiling studies have uncovered mutations in the SWI/SNF (SWItch / Sucrose Non-Fermentable) chromatin remodellin...
2023-04-26 - 2028-04-30 | Financiado

SALVOVAR: A EUROPEAN MULTI-DISCIPLINARY CLINICAL PROJECT MEANT TO IMPROVE THE MANAGEMENT OF PATIENTS WITH POOR... INSTITUT GUSTAVE ROUSSY participó en un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 The standard medical-and-surgical treatment of ovarian carcinoma patients relies on a systemic chemotherapy (carboplatin-paclitaxel), a tumo...
2023-04-24 - 2028-04-30 | Financiado

ETICAN: ECM and TFEB interplay: from building multidisciplinary devices to unravelling the missing link in c... INSTITUT GUSTAVE ROUSSY tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Over the last 30 years, researchers have shown that tumor cells not only need to accumulate oncogenic genetic alterations, but also rely on...
2023-04-21 - 2025-10-31 | Financiado

PREVALUNG EU: Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified i... INSTITUT GUSTAVE ROUSSY tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-STAYHLTH-02 Cardiovascular disease (CVD) and lung cancer (LC) are leading causes of deaths and intertwined chronic inflammatory processes associated wit...
2022-12-01 - 2027-11-30 | Financiado

ThermoBreast: An innovative non-contact and harmless screening modality set to change the course of breast cancer... INSTITUT GUSTAVE ROUSSY participó en un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Female breast cancer is the most diagnosed cancer worldwide. In 2020, the International Agency for Research on Cancer estimated more than 2....
2022-11-28 - 2026-12-31 | Financiado

PREVALUNG EU: Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified i... INSTITUT GUSTAVE ROUSSY tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-STAYHLTH-02 Cardiovascular disease (CVD) and lung cancer (LC) are leading causes of deaths and intertwined chronic inflammatory processes associated wit...
2022-11-24 - 2027-11-30 | Financiado

SilkPlatelet: Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based s... INSTITUT GUSTAVE ROUSSY participó en un HORIZON EUROPE: HORIZON-EIC-2021-TRANSITION-CHALLENGES-01 The generation of ex vivo functional megakaryocytes (MK) and platelets is questioning current transfusion medicine exclusive reliance on blo...
2022-07-25 - 2025-09-30 | Financiado

CGI-Clinics: Data driven cancer genome interpretation for personalised cancer treatment INSTITUT GUSTAVE ROUSSY participó en un HORIZON EUROPE: HORIZON-HLTH-2021-CARE-05 CGI-Clinics aims at improving personalised medicine in oncology by optimizing genomic data interpretation (after sequencing and before advis...
2022-05-20 - 2027-10-31 | Financiado